DanCann Pharma
0.56 DKK
+15.63 %
DANCAN
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
DanCann Pharma is a Danish life science company focused on discovering, developing, manufacturing, and commercialization of novel cannabinoid therapeutic products for medical use. The company was founded in 2018 due to the poor access for cannabinoid-based drugs and pharmaceuticals and with the purpose of developing and supplying medical cannabis, with a focus on consistency and quality provided by state-of-the-art and newly constructed manufacturing facilities (called Biotech Pharm1) which expect to be approved by the Danish authorities during 2022. DanCann recently acquired the Danish distributor of medical cannabis products, CannGros after which DanCann is now a fully vertical integrated operator within the market of cannabis for medical use, having development, manufacturing, and commercialization capabilities in-house.
Read moreRevenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
DanCann Pharma A/S delivers Q3 2025 Highlights - Leadership Transition, Strategic Progress, and Path Toward Delisting
Minutes of Extraordinary General Meeting held in DanCann Pharma A/S
Join Inderes community
Don't miss out - create an account and get all the possible benefits